Piper Jaffray Upgrades Vertex Pharmaceuticals To Overweight By: Benzinga via Benzinga October 13, 2014 at 08:09 AM EDT Analysts at Piper Jaffray upgraded Vertex Pharmaceuticals (NASDAQ: VRTX) from Neutral to Overweight. The price target for Vertex ... Read More >> Related Stocks: Vertex Pharmaceuticals